Omeros reported $11.32M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Adma Biologics USD 26.74M 5K Jun/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Cytokinetics USD 113.14M 8.75M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Immunic USD 3.45M 451K Dec/2025
Insmed USD 253.03M 5.56M Sep/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
MacroGenics USD 7.9M 1.81M Jun/2026
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 950.8M 858.99M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Rockwell Medical USD 4.04M 330K Jun/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
United Therapeutics USD 184.1M 22.6M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026